Multiple Sclerosis Clinical Trials in San Diego
View 14 new treatments for Multiple Sclerosis in San Diego, CA, and other areas near me, such as Carlsbad, Chula Vista, El Cajon, Escondido, Oceanside and Vista. Every day, Power helps hundreds of Multiple Sclerosis patients connect with leading medical research.Frexalimab for Multiple Sclerosis
Sanofi Clinic, Carlsbad + 1 more
This trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.Show More
Verified
Frexalimab for Multiple Sclerosis
Sanofi Clinic, La Jolla + 2 more
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: This event-driven study will have variable duration ranging from approximately 27 to 51 months. The study intervention duration will vary ranging from approximately 27 to 51 months. The number of scheduled visits will be up to 27 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months.Show More
Verified
Ofatumumab for Multiple Sclerosis
Novartis Clinic, San Diego + 1 more
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.Show More
No Placebo Trial
Fenebrutinib for Relapsing Multiple Sclerosis
Hoffmann-La Roche Clinic, Carlsbad + 2 more
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.Show More
Ocrelizumab vs Fingolimod for Pediatric Multiple Sclerosis
Hoffmann-La Roche Clinic, La Jolla + 2 more
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and \< 18 years over a flexible duration. The double-blind period will last until after the last participant randomized has completed 24 weeks.Show More
Peginterferon Beta-1a for Multiple Sclerosis
Biogen Clinic, La Jolla + 3 more
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants with RRMS in Part 1. In Part 2, the study will evaluate the long-term safety of BIIB017 and further describe safety and the long-term multiple sclerosis (MS) outcomes after BIIB017 treatment in participants who completed the study treatment at Week 96 in Part 1 of the study.Show More
No Placebo Trial
Tolebrutinib for Primary Progressive Multiple Sclerosis
Sanofi Clinic, La Jolla + 3 more
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relationship to efficacy and safety To evaluate pharmacodynamics of SAR442168Show More
ABP 692 vs Ocrelizumab for Multiple Sclerosis
Amgen Clinic, Carlsbad + 1 more
The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).Show More
No Placebo Trial
Ofatumumab + Siponimod vs Fingolimod for Pediatric Multiple Sclerosis
Novartis Clinic, San Diego + 2 more
This trial tests three medications in children and teens with multiple sclerosis to find effective treatments. The drugs work by reducing harmful immune cells or preventing them from attacking the nervous system.Show More
Remibrutinib vs Teriflunomide for Multiple Sclerosis
Novartis Clinic, Chula Vista + 2 more
This trial compares remibrutinib and teriflunomide in patients with relapsing multiple sclerosis. It aims to find out which medication is more effective and safer. Both drugs work by controlling the immune system to reduce relapses. Teriflunomide is an approved treatment for adults with this condition.Show More
No Placebo Trial
Frequently Asked Questions
How much do multiple sclerosis clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.
Do I need to be insured to participate in a medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
How do multiple sclerosis clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across multiple sclerosis trials in San Diego, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for multiple sclerosis patients is 6 Months.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.
Where in San Diego is research being conducted for multiple sclerosis?
In San Diego, the Novartis Investigative Site is conducting clinical trials for multiple sclerosis. Approximately 2 trials are ongoing as of the latest update.
What promising new drugs are being tested?
In San Diego, research for multiple sclerosis includes treatments like Monoclonal Antibodies and Sphingosine-1-Phosphate Receptor Modulators. Specific drugs such as Ofatumumab, Fingolimod, and Siponimod are being studied.